• 1
    Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 1994; 3: 17782
  • 2
    Newling DW. Update on urology – prostate cancer. 1 – The molecular basis for prostatic cancer: how it may influence treatment choice. Eur J Surg Oncol 1995; 21: 3105
  • 3
    Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 21524
  • 4
    Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European Perspective. Eur Urol 2003; 44: 6505
  • 5
    Mellon JK. The finasteride prostate cancer prevention trial (PCPT) – what have we learned? Eur J Cancer 2005; 41: 201622
  • 6
    Cohen YC, Liu KS, Heyden NL et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 136674
  • 7
    Tetu B, Srigley JR, Boivin JC et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 1991; 15: 11120
  • 8
    Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996; 14 (Suppl. 2): 2231
  • 9
    Yang XJ, Lecksell K, Short K et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53: 696700
  • 10
    Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004; 2: 22835
  • 11
    Lucia MS, Epstein JI, Goodman PJ et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 137583
  • 12
    Cussenot O, Azzouzi AR, Nicolaiew N et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007; 52: 10827
  • 13
    Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2, 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53: 24452
  • 14
    Thomas LN, Douglas RC, Lazier CB et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008; 179: 14751
  • 15
    Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003; 57: 1349
  • 16
    Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 13147
  • 17
    Thompson IM, Chi C, Ankerst DP et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 112833
  • 18
    Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 6670
  • 19
    Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila Pa) 2008; 1: 17481
  • 20
    Kaplan SA, Roehrborn CG, Meehan AG et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009; 73: 9359